FDA Warns 30 Telehealth Firms Over Misleading Compounded GLP-1 Ads

Signage outside the Food and Drug Administration (FDA) headquarters in White Oak, Md., on Aug. 29, 2020. Andrew Kelly/ReutersThe Food and Drug Administration (FDA) has issued 30 warning letters to companies that the agency said are making false or misleading claims about compounded GLP-1 products being offered on their websites.In its March 3 announcement, the FDA said that compounded drugs are not FDA-approved, which means the agency does not review their safety, effectiveness, or quality before they are marketed to the public. Compounded drugs are different from generic drugs, which are approved by the FDA.